Q3 2024 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Kiniksa Pharmaceuticals International PLC (KNSA) reported a 73% year-over-year growth in Arcalyst net product revenue, reaching $112.2 million for the third quarter.
- The company increased its full-year Arcalyst net sales guidance to between $410 million to $420 million, up from the previous range of $405 million to $415 million.
- Kiniksa Pharmaceuticals International PLC (KNSA) has a robust financial position with a positive annual cash flow, supporting growth investments across its business.
- The company has seen an increase in total prescribers from approximately 2,300 in Q2 to approximately 2,550 in Q3, indicating strong market penetration.
- Patient compliance remains high at above 85%, with greater than 90% payer approval of completed cases, reflecting strong satisfaction with Arcalyst.
- Despite the growth, Kiniksa Pharmaceuticals International PLC (KNSA) reported a net loss of $12.7 million for the third quarter of 2024.
- The company faces challenges in penetrating the market for first recurrence patients, with only 15% of prescriptions coming from this group.
- There is a significant delay in diagnosis for recurrent pericarditis, with patients reporting an average of 2.7 misdiagnoses before receiving the correct diagnosis.
- Operating expenses have increased due to costs associated with Arcalyst revenue growth, collaboration expenses, and R&D and SG&A driven largely by personnel costs.
- The company has not provided specific guidance on enrollment timelines for the Abiprubart phase two B study in Sjogren's disease, indicating potential uncertainties in clinical development.
Good day. And thank you for standing by. Welcome to the Kiniksa Pharmaceuticals third quarter, 2024 earnings conference call. At this time all participants are in a listen-only mode. Please be advised that today's conference is being recorded after the speaker's presentation. There will be a question and answer session to ask a question. Please press star 11 on your telephone and wait for your name to be announced. To withdraw your question. Please press star 11 again. I would now like to hand the conference over to your speaker today, Jonathan Kirschenbaum Investor Relations.
Thank you operator. Good morning, everyone and thank you for joining Kiniksa call to discuss our third quarter, 2024 financial results and recent portfolio execution. A press release highlighting these results can be found on our website under the investors section.
As for the agenda, our Chief Executive Officer Sanj K Patel will start with an introduction, Ross Moat, our Chief Commercial Officer will provide
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
